{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:31:05Z","timestamp":1794324665946,"version":"4.9.0"},"reference-count":0,"publisher":"ScopeMed","issue":"2","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/www.openveterinaryjournal.com\/?sec=licenseinfo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Open Vet. J."],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: \nAnemia is a major global health concern and a frequent complication of cancer chemotherapy. Patients with diabetes mellitus (DM) may experience cisplatin-induced anemia (CIA), driven primarily by nephrotoxicity and impaired erythropoiesis. However, the interaction between pre-existing DM and CIA remains insufficiently understood, and preclinical models are limited.\n\nAim: \nTo determine the optimal single-dose, acute cisplatin regimen capable of inducing moderate anemia in a streptozotocin\u2013nicotinamide (STZ\u2013NA) type 2 diabetic Sprague Dawley rat model. \n\nMethods: \nTwenty male Sprague Dawley rats were induced diabetic using nicotinamide (230 mg\/kg BW, i.p.) followed by streptozotocin (65 mg\/kg BW, i.v.). Diabetes was confirmed 72 h later by fasting blood glucose (FBG) \u2265 150 mg\/dL, with repeat measurements performed to ensure stability before cisplatin administration. Diabetic rats were randomized into four groups (n = 5 per group): control (saline) or a single IV injection of cisplatin at 4, 6, or 8 mg\/kg BW. Hemoglobin (HGB), platelet (PLT), white blood cell (WBC), and neutrophil (NEU) counts were measured on days 7, 14, and 21 after injection. The optimal dose was defined as inducing &gt;15% HGB reduction without mortality.\n\nResults: \nCisplatin induced a significant dose-dependent reduction in HGB. The 4 mg\/kg BW group developed mild anemia, whereas the 6 and 8 mg\/kg BW doses produced moderate anemia (&gt;15% HGB reduction) beginning on day 14 and maintained it through day 21 (\u224820.8\u201321.1%). All treated groups showed significant thrombocytopenia (decreased PLT count), leukocytosis (increased WBC count), and absolute neutrophilia (increased NEU count with increased WBC count). Weight loss (15.1%\u201316.2%) occurred across the groups, with the 6-mg\/kg BW cohort exhibiting a less severe reduction than the 8-mg\/kg BW group. No mortality occurred in any of the groups.\n\nConclusion: \nA single dose of cisplatin (6 mg\/kg body weight) induces moderate, non-lethal CIA in diabetic Sprague Dawley rats while preserving tolerability. This preliminary study provides foundational dose-response data for developing diabetic-specific CIA models. However, additional validation incorporating comprehensive hematological and mechanistic assessments is required.<\/jats:p>","DOI":"10.5455\/ovj.2026.v16.i2.29","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:03:12Z","timestamp":1772280192000},"page":"1090","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Determination of the optimal cisplatin dose to induce anemia in streptozotocin-nicotinamide-induced type 2 diabetic rats: A preliminary study&lt;\/b&gt;"],"prefix":"10.5455","volume":"16","author":[{"given":"Agus","family":"Sunggoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramasari","family":"Dirgahayu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bambang","family":"Purwanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eti","family":"Pamungkasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Warsita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risya","family":"Cilmiaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiana","family":"Wardhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohanna","family":"Dewi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3407","container-title":["Open Veterinary Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.bibliomed.org\/fulltextpdf.php?mno=285025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:19:38Z","timestamp":1791483578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.openveterinaryjournal.com\/?mno=285025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5455\/ovj.2026.v16.i2.29","relation":{},"ISSN":["2226-4485"],"issn-type":[{"value":"2226-4485","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}